Amgen recalls MVASI (bevaciz:awwb) injections due to potential container leaks. This risk affects patients receiving the drug for cancer treatment. Contact Amgen for details.
“Amgen MVASI injection recall: Loose container risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/34802-amgen-mvasi-injection-recall-loose-container-risk. Based on FDA recall #D-0855-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0855-2022%22&limit=1).
The FDA announced on May 2, 2022, that Amgen is recalling MVASI (bevacizumab-awwb) injection due to a defective container with a loose crimp that risks loss of integrity. The recall affects 15,823 single-dose vials distributed nationwide in the USA, Egypt, and Lithuania.
How to tell if you have it
Brand: Amgen
Product: MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only
NDC: 55513-0206-01
Lots: 1142258, 1143196
Expiration: 09/24
The hazard
The vials have a defective container with a loose crimp defect, which creates the potential for loss of container integrity. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show Amgen has issued six other recalls since September 17, 2013. Recent brand recalls include Sensipar tablets on June 4, 2026, and Neupogen Injection on February 27, 2025. Other recent recalls of similar products include Sagent Busulfan Injection (May 4, 2026) and Baxter Vancomycin Injection (August 6, 2026).
How to tell if you have this one
Check for the product name MVASI (bevacizumab-awwb), 100 mg/4 ml single-dose vial, manufactured by Amgen in Thousand Oaks, CA. Lot numbers 1142258 or 1143196 with expiration date 09/24.
Brand
Amgen
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Container Integrity
Inspect the vial for loose crimp defects that might cause leaks.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the USA, Egypt and Lithuania.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 7 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0855-2022 (May 2, 2022) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0855-2022 to see it in context.
Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.